Sunovion Pharmaceuticals’ drug Latuda has been approved by Canada’s public health agency for the treatment of adolescents with schizophrenia, Sunovion said last week.
Latuda was approved based on results from a study finding patients treated with Latuda versus a placebo demonstrated statistically significant and clinically meaningful improvement in symptoms of schizophrenia. The drug is already indicated in Canada to treat the manifestations of schizophrenia and the acute management of depressive episodes associated with bipolar I disorder in adults.
Health Canada is currently reviewing another proposal from Sunovion to expand the use of Latuda to children and adolescents with the major depressive episodes associated with bipolar I disorder as a singular treatment.
